Publications by authors named "Linda Bouhlel"
Article Synopsis
- The study investigates immune-related adverse events (irAEs) in patients with advanced non-small-cell lung cancer (NSCLC) treated with nivolumab, finding that irAEs are linked to better survival outcomes.
- Out of 69 patients reviewed from 2015 to 2017, those who experienced irAEs generally had improved overall survival and progression-free survival rates compared to those who did not.
- The research highlights that a higher number of irAEs correlates positively with tumor response, suggesting that developing more than one irAE may indicate a favorable treatment response.
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR. LB is not presently recommended in daily practice for the diagnosis of NSCLC. Areas covered: We report the diagnosis of a NSCLC in a patient with bilateral ocular metastases after detection of a deletion in exon 19 of EGFR when using plasma DNA.
View Article and Find Full Text PDF